How Do You Navigate GxP Compliance?

By Jim Brooks, Lead Platform Product Manager for GxP Strategy, IDBS

With FDA warning letters more than doubling in a single year, the pressure on drug and biologic manufacturers to maintain impeccable data integrity has never been higher. Achieving GxP compliance is often hindered by fragmented data systems that create silos, slow down quality assurance, and increase the risk of manual error. To move beyond these administrative burdens, organizations are transitioning toward centralized digital platforms that automate validation and provide real-time visibility across the product lifecycle. These integrated systems ensure that audit trails and electronic signatures are embedded directly into the workflow, significantly reducing the time scientists spend on manual documentation. By prioritizing data accessibility and secure, unified records, companies can transform compliance from a reactive hurdle into a streamlined, inspection-ready standard. Explore the full blog post to learn actionable strategies for optimizing your operational efficiency and fostering a culture of continuous improvement.